Actively Recruiting
Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients From Molecular Aspects to Clinical Indications
Led by Chiara Lanzani · Updated on 2025-08-13
300
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how SGLT2 inhibitor therapy affects elderly patients, focusing on both kidney and metabolic aspects. This observational project combines clinical and biological data and uses advanced Bayesian statistics to explore how risk factors relate to patient outcomes after treatment with SGLT2 inhibitors. The study aims to better understand the effects of these drugs in people aged 65 and older with various conditions like diabetes, heart, and kidney diseases. Participants are patients aged 65 or older who have been prescribed an SGLT2 inhibitor for any clinical reason and have not yet started this therapy. The study observes these patients from the time of prescription and tracks their health status over six months of treatment. There are no experimental interventions since the therapy is given as part of routine care following clinical guidelines. During the study, researchers will assess patient health before and after six months of treatment using the Frailty Index to measure changes in overall health status. Participants will provide clinical and biological information over this period, allowing detailed monitoring of treatment effects. The study begins in February 2025 and continues until February 2027, focusing on real-world outcomes in elderly patients receiving SGLT2 inhibitors.
CONDITIONS
Brief Title
Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant is willing and able to give informed consent for participation in the study
- Patients must be enrolled also in MED-Cli and MED-Mol studies by signing both informed consents
- The medical product is standard of care and prescribed according to clinical practice independent of the study
- Age 65 years or older
- Participant has not yet started the prescribed SGLT2i therapy
- Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines
You will not qualify if you...
- Current or previous use of SGLT2i
- Inability to sign the informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants who have just been prescribed SGLT2i therapy are observed to assess health status changes over time.
Visits as per routine clinical practice over 6 months
Trial Site Locations
Total: 1 location
1
San Raffaele Hospital
Milan, Milan, Italy, 20132
Actively Recruiting
Research Team
C
Chiara Livia Lanzani, professor
F
Federica Guerra, Dr
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here